News of Note—GlaxoSmithKline, VLP Therapeutics and more


Here is some other vaccine news of note for the week:

> GlaxoSmithKline's vaccine sales grew 16% last year to £5.9 billion ($7.64 billion). Shingrix sales hit £784 million ($1 billion) in its first full year on the market. Release

> Gaithersburg, Maryland-based VLP Therapeutics said it plans to kick off an initial clinical study of its malaria vaccine candidate. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Officials in Kentucky are looking into vaccine-associated infections in Kentucky, Ohio and Indiana due to possible improper handling and storage by a service provider. Release (PDF)


Suggested Articles

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.

Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.